• Candel Therapeutics, Inc. reported second-quarter 2026 results, with net loss widening to US$38.91 million and basic and diluted loss per share from continuing operations at US$0.52, while first-half 2026 net loss reached US$47.77 million compared with net income in the prior-year period.
• The sharp shift from profitability to loss over six months highlights a significant change in Candel Therapeutics’ operating profile that investors will scrutinize closely.
• We will now examine how this sharp widening of losses shapes Candel Therapeutics’ investment narrative and what it could mean for investors.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Candel Therapeutics' Investment Narrative?

To own Candel Therapeutics today, you really have to believe in CAN-2409 as a platform that can move from promising prostate cancer data and regulatory designations into an approved, commercial product, while also opening doors in NSCLC and other solid tumors. The recent second-quarter 2026 results, with net loss jumping to US$38.91 million and first-half losses sharply higher, bring the funding question to the forefront and could accelerate the timing or scale of any future capital raises, especially after such a strong share price run. That does not change the near term clinical catalysts like the planned prostate cancer BLA filing in late 2026 or progress in the AURORA lung trial, but it does raise the stakes around execution discipline, cash burn, and potential shareholder dilution as the company pushes multiple late stage programs forward.

However, that widening loss profile carries a funding risk that existing shareholders should not ignore. Candel Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

With only two fair value estimates from the Simply Wall St Community, opinions span from about US$21 to over US$314 per share, underscoring how differently people are sizing up Candel’s upside against the heightened cash burn and dilution risk highlighted above. You are seeing a wide gap between optimism around CAN-2409’s late stage catalysts and concern about how the company funds the journey, which is worth unpacking before deciding what this stock means for your portfolio.

Explore 2 other fair value estimates on Candel Therapeutics - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Candel Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Candel Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Candel Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.